What does this research mean for the field?

The rate of carbapenem resistance in Klebsiella pneumoniae isolates from blood cultures increased from 9.2% in 2014-2017 to 34.5% in 2019-2024, with a significant prevalence of metallo-β-lactamase-producing strains identified. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

This study aims to analyze the change in carbapenem resistance profiles and phenotypes of Klebsiella pneumoniae over a decade.

March 17, 2026Open Access

Change in the Carbapenem Resistance Profile and Presentation of Resistance Phenotypes in Klebsiella Pneumoniae: Analysis of Blood Cultures From a Private Tertiary Hospital in Porto Alegre Between 2014 and 2024

Key Points

This study aims to analyze the change in carbapenem resistance profiles and phenotypes of Klebsiella pneumoniae over a decade.
Retrospective cross-sectional analysis of blood cultures positive for Klebsiella pneumoniae from 2014 to 2024.
Evaluation of susceptibility to meropenem using CLSI and BrCAST breakpoints for disk diffusion and gradient strip tests.
Assessment of carbapenemase production and resistance mechanisms among isolated strains.
Overall meropenem resistance rate was 27.3% across the studied period.
Resistance increased from 9.2% (2014-2017) to 34.5% (2019-2024).
95% of meropenem-resistant isolates produced carbapenemases, with serine β-lactamases remaining prevalent at 95.3%.
Metallo-β-lactamase producers were first identified in 2019, reaching 57% in 2024.
Co-producing strains (SBL and MBL) also rose significantly, constituting 44% of resistant isolates in 2024.

Abstract

In the face of increasing antimicrobial resistance, in 2017 the World Health Organization listed priority bacteria for prevention and treatment. Among these are carbapenem-resistant Enterobacterales , with Klebsiella pneumoniae being the main representative. This study aims to describe the evolution of carbapenem resistance and the resistance phenotypes of K. pneumoniae isolated in blood cultures. Retrospective cross-sectional study with data from blood cultures positive for K. pneumoniae from a tertiary hospital between 2014 and 2024. Susceptibility to meropenem was evaluated according to the breakpoints proposed by CLSI (until 2020) or BrCAST (from 2021) for disk diffusion analysis (or gradient strip when resistance to meropenem was detected), and carbapenemase production was evaluated by phenotypic tests. Blood cultures from the same patient with identical resistance profiles during the same hospitalization were excluded. The outcomes evaluated were the proportion of susceptibility to meropenem, the proportion of carbapenem-resistant K. pneumoniae by carbapenemase production, and the proportion of enzymatic resistance mechanisms detected. From 2014 to 2024, 1559 blood cultures with growth of K. pneumoniae were identified in 726 different patients. The overall meropenem resistance rate was 27.3% (426). From 2014 to 2017, meropenem resistance occurred in 9.2% of isolates (37/402); in 2018 it increased to 24% (23/96); and from 2019 to 2024 it remained at 34.5% (366/1061). Almost all (95% – 403/426) of the meropenem-resistant isolates produced carbapenemases. Among these resistant isolates, the production of serine β-lactamases (SBL) remained around 95.3% (384/403). The first isolates producing metallo-β-lactamases (MBL) were identified in 2019, with an increasing prevalence in recent years, reaching 57% (30/52) of isolates in 2024. Co-producing K. pneumoniae (SBL and MBL) were identified from 2021 and have also increased in proportion in recent years, reaching 44% (23/52) in 2024. The increasing carbapenem resistance in K. pneumoniae isolates is concerning. The rising prevalence of MBL-producing K. pneumoniae impacts the choice of new antimicrobials available in Brazil, such as ceftazidime-avibactam, which lacks activity against this phenotype.

Read Full Paperexternally

Ask AI

Helpful

Bookmark

View Full Paper